Comparison of 1-Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study

IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY JGH Open Pub Date : 2025-02-17 DOI:10.1002/jgh3.70106

Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi-Thu Nguyen, Nga Thi Dinh, Lien Thi-Phuong Nguyen, Khien Van Vu, Minh Cuong Duong

{"title":"Comparison of 1-Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study","authors":"Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi-Thu Nguyen, Nga Thi Dinh, Lien Thi-Phuong Nguyen, Khien Van Vu, Minh Cuong Duong","doi":"10.1002/jgh3.70106","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background/Aims</h3>\n \n <p>The differences in the clinical course of Crohn's disease (CD) and ulcerative colitis (UC) among Asian countries remain unknown. Thus, we compared the clinical characteristics, treatment, and one-year outcomes of newly diagnosed inflammatory bowel disease (IBD) patients between Vietnam and Korea.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective cohort study was conducted at seven tertiary hospitals in these countries between January 2020 and January 2021. Data on demographics, diseases, treatment, and outcomes during 1 year after diagnosis were collected.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 225 patients (60 from Vietnam and 165 from Korea), 140 and 85 were diagnosed with UC and CD, respectively. Severe activity (<i>p</i> < 0.01) and extensive colitis (<i>p</i> < 0.01) in UC, along with complicated behavior in CD (<i>p</i> < 0.01), were more frequently observed in Vietnamese patients compared to Korean patients. The proportion of UC patients using corticosteroids (<i>p</i> < 0.01), immunomodulators (<i>p</i> < 0.01), and biologics (<i>p</i> = 0.026) was significantly higher in Vietnam. In contrast, the proportion of UC patients using topical mesalamine (<i>p</i> < 0.01) was significantly higher in Korea. The intervals from CD diagnosis to biologic therapy initiation (<i>p</i> = 0.04), as well as from UC diagnosis to corticosteroid (<i>p</i> < 0.01), immunomodulator (<i>p</i> < 0.01), and biologic therapy (<i>p</i> < 0.01) commencement, were significantly shorter in Vietnamese patients compared to Korean patients. However, the proportions of endoscopic healing and complications at 1-year follow-up did not significantly differ between the countries (<i>p</i> > 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Although Vietnamese IBD patients had higher baseline clinical and phenotypic severity than their Korean counterparts, no significant differences in short-term outcomes were observed, potentially reflecting the impact of the higher rate and early biologic usage in Vietnamese patients.</p>\n </section>\n </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 2","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70106","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/Aims

The differences in the clinical course of Crohn's disease (CD) and ulcerative colitis (UC) among Asian countries remain unknown. Thus, we compared the clinical characteristics, treatment, and one-year outcomes of newly diagnosed inflammatory bowel disease (IBD) patients between Vietnam and Korea.

Methods

A retrospective cohort study was conducted at seven tertiary hospitals in these countries between January 2020 and January 2021. Data on demographics, diseases, treatment, and outcomes during 1 year after diagnosis were collected.

Results

Among 225 patients (60 from Vietnam and 165 from Korea), 140 and 85 were diagnosed with UC and CD, respectively. Severe activity (p < 0.01) and extensive colitis (p < 0.01) in UC, along with complicated behavior in CD (p < 0.01), were more frequently observed in Vietnamese patients compared to Korean patients. The proportion of UC patients using corticosteroids (p < 0.01), immunomodulators (p < 0.01), and biologics (p = 0.026) was significantly higher in Vietnam. In contrast, the proportion of UC patients using topical mesalamine (p < 0.01) was significantly higher in Korea. The intervals from CD diagnosis to biologic therapy initiation (p = 0.04), as well as from UC diagnosis to corticosteroid (p < 0.01), immunomodulator (p < 0.01), and biologic therapy (p < 0.01) commencement, were significantly shorter in Vietnamese patients compared to Korean patients. However, the proportions of endoscopic healing and complications at 1-year follow-up did not significantly differ between the countries (p > 0.05).

Conclusions

Although Vietnamese IBD patients had higher baseline clinical and phenotypic severity than their Korean counterparts, no significant differences in short-term outcomes were observed, potentially reflecting the impact of the higher rate and early biologic usage in Vietnamese patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

越南和韩国新诊断炎症性肠病患者1年临床病程的比较：一项多国、多中心回顾性队列研究

背景/目的克罗恩病（CD）和溃疡性结肠炎（UC）在亚洲国家的临床病程差异尚不清楚。因此，我们比较了越南和韩国新诊断的炎症性肠病（IBD）患者的临床特征、治疗和一年预后。方法于2020年1月至2021年1月在这些国家的7家三级医院进行回顾性队列研究。收集诊断后1年内的人口统计学、疾病、治疗和结局数据。结果225例患者（越南60例，韩国165例）中，诊断为UC和CD的分别为140例和85例。UC患者的严重活动（p < 0.01）和广泛结肠炎（p < 0.01）以及CD患者的复杂行为（p < 0.01）在越南患者中比韩国患者更常见。越南UC患者使用皮质类固醇（p < 0.01）、免疫调节剂（p < 0.01）和生物制剂（p = 0.026）的比例显著较高。相比之下，韩国UC患者局部使用美沙拉明的比例明显更高（p < 0.01）。越南患者从CD诊断到生物治疗开始（p = 0.04），以及从UC诊断到皮质类固醇（p < 0.01）、免疫调节剂（p < 0.01）和生物治疗开始（p < 0.01）的间隔时间明显短于韩国患者。然而，在1年随访中，内镜下愈合和并发症的比例在各国之间没有显著差异（p > 0.05）。结论：尽管越南IBD患者的基线临床和表型严重程度高于韩国患者，但短期结果没有观察到显著差异，这可能反映了越南患者较高的发病率和早期生物制剂使用的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊